- Kevin Young is coming back to Gilead to take on the role of chief operating officer, replacing Paul Carter.
- Young left his position as executive vice president of commercial operations at Gilead in 2014, after 10 years.
- In addition, Gilead appointed Dr. Martin Silverstein EVP of strategy. He will be in charge of overseeing corporate development, commercial planning, and alliance management, according to the San Francisco Business Times.
When Young left Gilead in 2014, he had overseen the launch of several compounds in the company's HIV/AIDS portfolio, and also played a significant role in the launch of Gilead's hep C blockbuster Sovaldi. During his tenure, Gilead's revenues grew 13-fold to $11.2 billion. Last year, revenues hit $32 billion, largely because of Sovaldi and Gilead's other hep C blockbuster, Harvoni.
"I am delighted to welcome Kevin back to Gilead in a full-time capacity," Gilead President and CEO John Milligan said in a statement. "His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company."